trial

A RCT Study in Schizophrenia Relapse Prevention

NCTId NCT01885923
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Unknown
Enrollment 150 (estimated)
Sponsored by Prague Psychiatric Center
Primary completion 2014-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
150 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2012-08
Primary completion
2014-07
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
ITAREPS

Sponsors

Prague Psychiatric CenterLead Sponsor

Investigators

1
Filip Spaniel, MD, PhDStudy Director

Sites

1 total
Prague, Czechia

Facts & assertions

4 sourced
Enrollment
150
Phase
NA
Primary Completion Date
2014-07
Status
UNKNOWN
relationships
The graph out of here
drug
ITAREPS
drug
lead_sponsor
Prague Psychiatric Center
company
indication
Relapse Schizophrenia
indication
Schizophrenia
indication
investigator
Filip Spaniel, MD, PhD
person